287 related articles for article (PubMed ID: 31227054)
1. Radionuclide Therapy of Metastatic Prostate Cancer.
Kratochwil C; Haberkorn U; Giesel FL
Semin Nucl Med; 2019 Jul; 49(4):313-325. PubMed ID: 31227054
[TBL] [Abstract][Full Text] [Related]
2. [PSMA-targeted radioligand therapy in prostate cancer].
Heck MM; Retz M; Tauber R; Knorr K; Kratochwil C; Eiber M
Urologe A; 2017 Jan; 56(1):32-39. PubMed ID: 27885457
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Third-line treatment and
von Eyben FE; Roviello G; Kiljunen T; Uprimny C; Virgolini I; Kairemo K; Joensuu T
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):496-508. PubMed ID: 29247284
[TBL] [Abstract][Full Text] [Related]
5. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.
Kratochwil C; Giesel FL; Stefanova M; Benešová M; Bronzel M; Afshar-Oromieh A; Mier W; Eder M; Kopka K; Haberkorn U
J Nucl Med; 2016 Aug; 57(8):1170-6. PubMed ID: 26985056
[TBL] [Abstract][Full Text] [Related]
6.
Fendler WP; Rahbar K; Herrmann K; Kratochwil C; Eiber M
J Nucl Med; 2017 Aug; 58(8):1196-1200. PubMed ID: 28663195
[No Abstract] [Full Text] [Related]
7. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
9. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.
Rahbar K; Boegemann M; Yordanova A; Eveslage M; Schäfers M; Essler M; Ahmadzadehfar H
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):12-19. PubMed ID: 29026946
[TBL] [Abstract][Full Text] [Related]
10. A Prospective Comparison of
Harmon SA; Bergvall E; Mena E; Shih JH; Adler S; McKinney Y; Mehralivand S; Citrin DE; Couvillon A; Madan RA; Gulley JL; Mease RC; Jacobs PM; Pomper MG; Turkbey B; Choyke PL; Lindenberg ML
J Nucl Med; 2018 Nov; 59(11):1665-1671. PubMed ID: 29602821
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific membrane antigen radioligand therapy of prostate cancer.
Beheshti M; Heinzel A; von Mallek D; Filss C; Mottaghy FM
Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):29-36. PubMed ID: 30644306
[TBL] [Abstract][Full Text] [Related]
12. Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer.
Kratochwil C; Afshar-Oromieh A; Kopka K; Haberkorn U; Giesel FL
Semin Nucl Med; 2016 Sep; 46(5):405-18. PubMed ID: 27553466
[TBL] [Abstract][Full Text] [Related]
13. New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy.
Haberkorn U; Eder M; Kopka K; Babich JW; Eisenhut M
Clin Cancer Res; 2016 Jan; 22(1):9-15. PubMed ID: 26728408
[TBL] [Abstract][Full Text] [Related]
14. Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer.
Heck MM; Retz M; D'Alessandria C; Rauscher I; Scheidhauer K; Maurer T; Storz E; Janssen F; Schottelius M; Wester HJ; Gschwend JE; Schwaiger M; Tauber R; Eiber M
J Urol; 2016 Aug; 196(2):382-91. PubMed ID: 26964917
[TBL] [Abstract][Full Text] [Related]
15. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.
Delker A; Fendler WP; Kratochwil C; Brunegraf A; Gosewisch A; Gildehaus FJ; Tritschler S; Stief CG; Kopka K; Haberkorn U; Bartenstein P; Böning G
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):42-51. PubMed ID: 26318602
[TBL] [Abstract][Full Text] [Related]
16. Lutetium
Emmett L; Willowson K; Violet J; Shin J; Blanksby A; Lee J
J Med Radiat Sci; 2017 Mar; 64(1):52-60. PubMed ID: 28303694
[TBL] [Abstract][Full Text] [Related]
17. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
[TBL] [Abstract][Full Text] [Related]
18. Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors.
Kelly J; Amor-Coarasa A; Ponnala S; Nikolopoulou A; Williams C; Schlyer D; Zhao Y; Kim D; Babich JW
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1841-1851. PubMed ID: 29623376
[TBL] [Abstract][Full Text] [Related]
19. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
Barrio M; Fendler WP; Czernin J; Herrmann K
Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
[TBL] [Abstract][Full Text] [Related]
20. Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window.
Kelly JM; Amor-Coarasa A; Ponnala S; Nikolopoulou A; Williams C; DiMagno SG; Babich JW
J Nucl Med; 2019 May; 60(5):656-663. PubMed ID: 30552199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
